MINITRAN

Clinical safety rating: caution

Comprehensive clinical and safety monograph for MINITRAN (MINITRAN).

How it works

Nitroglycerin is converted to nitric oxide (NO) in vascular smooth muscle, which activates guanylyl cyclase, increasing cGMP levels. This leads to dephosphorylation of myosin light chains and vasodilation, particularly in venous capacitance vessels and coronary arteries, reducing preload and afterload.

What the body does with it

Metabolism	Rapidly metabolized in the liver by glutathione-organic nitrate reductase, with minor contributions from vascular wall and RBC metabolism. Metabolites include 1,2-glyceryl dinitrate and 1,3-glyceryl dinitrate.
Excretion	Primarily renal excretion of inactive metabolites; less than 1% excreted unchanged. Biliary/fecal elimination is minimal.
Half-life	Terminal half-life is approximately 1-4 minutes for nitroglycerin; clinical effect duration is longer due to tissue distribution.
Protein binding	Approximately 60% bound to plasma proteins (albumin).
Volume of Distribution	Vd is about 3 L/kg, indicating extensive tissue distribution.
Bioavailability	Transdermal: approximately 70-80% of the dose reaches systemic circulation.
Onset of Action	Transdermal: 30-60 minutes; therapeutic effect delayed due to slow absorption.
Duration of Action	Transdermal: 8-12 hours; requires daily patch-off period to prevent tolerance.

Classification & Brands

Dosing & administration

Minitran (nitroglycerin transdermal) is applied as a transdermal patch. Initial dose: 0.2-0.4 mg/hour applied once daily. Titrate based on response and tolerance. Maximum dose: 0.8 mg/hour. The patch is worn for 12-14 hours daily with a 10-12 hour nitrate-free interval to prevent tolerance.

Dosage form	FILM, EXTENDED RELEASE
Renal impairment	No specific dose adjustment required for renal impairment. However, patients with severe renal insufficiency (CrCl <30 mL/min) may have increased risk of adverse effects; monitor closely.
Liver impairment	No specific dose adjustment recommended for Child-Pugh A or B. For Child-Pugh C (severe hepatic impairment), consider reducing dose due to reduced metabolism and increased risk of hypotension; use with caution.
Pediatric use	Safety and effectiveness in pediatric patients have not been established. Use only under expert guidance. Typical initial dose: 0.1-0.2 mg/hour transdermally, titrated cautiously based on clinical response and tolerance.
Geriatric use	Elderly patients may be more sensitive to the hypotensive effects. Start at the lower end of dosing range (0.2 mg/hour) and titrate slowly. Monitor blood pressure and heart rate regularly.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for MINITRAN (MINITRAN).

Breastfeeding	Likely excreted in breast milk. M/P ratio not established. Use with caution; monitor infant for hypotension.
Teratogenic Risk	Category C. Animal studies show fetal harm; no adequate human studies. Use only if maternal benefit outweighs risk. First trimester: possible teratogenic effects. Second/third trimesters: risk of fetal bradycardia, hypotension, and decreased placental perfusion.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

Do not use MINITRAN in patients taking phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil, vardenafil) as this can cause severe hypotension. Additionally, MINITRAN should not be used in patients with early myocardial infarction or severe anemia.

Side Effect Profile

Serious Effects

Absolute Contraindications

Concurrent use of phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil, vardenafil); severe anemia; increased intracranial pressure (e.g., head trauma, cerebral hemorrhage); acute circulatory failure; hypersensitivity to nitrates.

Clinical Precautions

Precautions

Hypotension; paradoxical bradycardia; tolerance (need for nitrate-free interval); exacerbation of angina with abrupt discontinuation; use with caution in patients with volume depletion, hypotension, or hypertrophic cardiomyopathy.

Clinical Tips & Counseling

Drug interactions

Loading safety data…

MINITRAN

Clinical safety rating: caution

Comprehensive clinical and safety monograph for MINITRAN (MINITRAN).

How it works

What the body does with it

Metabolism	Rapidly metabolized in the liver by glutathione-organic nitrate reductase, with minor contributions from vascular wall and RBC metabolism. Metabolites include 1,2-glyceryl dinitrate and 1,3-glyceryl dinitrate.
Excretion	Primarily renal excretion of inactive metabolites; less than 1% excreted unchanged. Biliary/fecal elimination is minimal.
Half-life	Terminal half-life is approximately 1-4 minutes for nitroglycerin; clinical effect duration is longer due to tissue distribution.
Protein binding	Approximately 60% bound to plasma proteins (albumin).
Volume of Distribution	Vd is about 3 L/kg, indicating extensive tissue distribution.
Bioavailability	Transdermal: approximately 70-80% of the dose reaches systemic circulation.
Onset of Action	Transdermal: 30-60 minutes; therapeutic effect delayed due to slow absorption.
Duration of Action	Transdermal: 8-12 hours; requires daily patch-off period to prevent tolerance.

Classification & Brands

Dosing & administration

Dosage form	FILM, EXTENDED RELEASE
Renal impairment	No specific dose adjustment required for renal impairment. However, patients with severe renal insufficiency (CrCl <30 mL/min) may have increased risk of adverse effects; monitor closely.
Liver impairment	No specific dose adjustment recommended for Child-Pugh A or B. For Child-Pugh C (severe hepatic impairment), consider reducing dose due to reduced metabolism and increased risk of hypotension; use with caution.
Pediatric use	Safety and effectiveness in pediatric patients have not been established. Use only under expert guidance. Typical initial dose: 0.1-0.2 mg/hour transdermally, titrated cautiously based on clinical response and tolerance.
Geriatric use	Elderly patients may be more sensitive to the hypotensive effects. Start at the lower end of dosing range (0.2 mg/hour) and titrate slowly. Monitor blood pressure and heart rate regularly.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for MINITRAN (MINITRAN).

Breastfeeding	Likely excreted in breast milk. M/P ratio not established. Use with caution; monitor infant for hypotension.
Teratogenic Risk	Category C. Animal studies show fetal harm; no adequate human studies. Use only if maternal benefit outweighs risk. First trimester: possible teratogenic effects. Second/third trimesters: risk of fetal bradycardia, hypotension, and decreased placental perfusion.
Fetal Monitoring